卡培他滨联合肝动脉插管化疗栓塞治疗大肠癌肝转移的临床研究  

Study on capecitabine combined with TACE for the liver metastasis from colorectal carcinoma

作　　者：张群[1] 杨麒麟[1] 

机构地区：[1]四川省资阳市人民医院肿瘤科,四川资阳641300

出　　处：《现代肿瘤医学》2010年第7期1378-1380,共3页Journal of Modern Oncology

摘　　要：目的:探讨卡培他滨联合肝动脉插管化疗栓塞治疗大肠癌肝转移的临床应用及疗效。方法:采用随机分组方法将56例患者分为两组,治疗组28例,对照组28例。治疗组采用TACE 1周后口服希罗达,每日2500mg/m^2,分两次口服,连续服用2周,停药1周为1个疗程。对照组单纯采用TACE治疗。结果:经过2个疗程治疗后,治疗组与对照组的近期疗效有效率分别为71.4%,28.6%,两组间存在显著差异(P<0.05);两组肝内肿块血流信号控制:完全不可见42.9%,14.3%,部分可见50%,35.7%,血流信号丰富7.1%,50%;两组中位生存期分别为18月,14月(P<0.05)。服用希罗达主要不良反应为手足综合症,腹泻,骨髓抑制,肝功受损,多为Ⅰ-Ⅱ级,患者多可耐受。结论:卡培他滨联合TACE是治疗大肠癌肝转移安全、有效的方法。Objective：To evaluate the clinical efficacy and curative effect of capecitabine combined with TACE for the liver metastasis from colorectal carcinoma. Methods： The 56 patients were divided into two groups randomly. The treatment group： （28 patients） one week after TACE , received oral capecitabine（xeloda） at 2500mg/m^2, twice daily for 14 days followed by one week rest period. Four weeks was a course of treatment. The control group： （28 patients） received TACE only. Results： After two courses of treatment, the total efficiency of treatment group and control group were 71.4 % ,28.6%, （P 〈 0.05 ）, blood of tumor were changed, nothing 42.9%, 14.3 % ;weaken 50% , 35.7 % ;unchanged 7.1% ,50%. The median survival times were 18 months and 14 months respectively （P 〈0.05）. The most common side - effects of Xeloda were hand - foot syndrome, diarrhea, myelosuppress and liver toxicity. Most of these toxicities were tolerable at grade Ⅰ - Ⅱ. Conclusion： Capecitabine combined with TACE was safe and effective for liver metastasis from colorectal carcinoma.

关 键 词：卡培他滨 肝动脉插管化疗栓塞 大肠癌肝转移 联合 

分 类 号：R735.3[医药卫生—肿瘤]